[Effect of Protein Kinase A Activation on Aggregation Function of Platelets].

Meng-Xiao Jiang,Jun Liu,Kang-Xi Zhou,Hong-Lei Ye,Ren-Ping Hu,Rong Yan,Chang-Geng Ruan,Ke-Sheng Dai

DOI: https://doi.org/10.19746/j.cnki.issn.1009-2137.2020.03.030

2020-01-01

Abstract:PKA activation inhibits agonists-induced platelet aggregation.

What problem does this paper attempt to address?

Role of Camp-Dependent Protein Kinase in the Regulation of Platelet Procoagulant Activity

Rong Yan,Zhicheng Wang,Yanhong Yuan,Hong Cheng,Kesheng Dai

DOI: https://doi.org/10.1016/j.abb.2009.02.014

IF: 4.114

2009-01-01

Archives of Biochemistry and Biophysics

Abstract:The membrane microparticle (MP) formation and phosphatidylserine (PS) exposure evoked by platelet activation provide catalytic surfaces for thrombin generation. Several reports have indicated the effects of cAMP-elevating agents on agonist-induced MP formation and PS exposure; however, the mechanism still remains unclear. Here we show that inhibition of basal cyclic AMP-dependent protein kinase (PKA) activity incurred platelet MP formation and PS exposure. Pretreatment of platelets with cAMP-elevating agent, forskolin, abolished thrombin plus collagen-induced MP formation and PS exposure, and obviously decreased calcium ionophore-evoked MP shedding. Moreover, the inhibitory effects of forskolin on agonists-induced MP formation and PS exposure were reversed by the PKA inhibitor H89. PKA inhibitor-induced MP formation was dose-dependently inhibited by calpain inhibitor MDL28170, and forskolin abrogated thrombin plus collagen-induced calpain activation. In conclusion, PKA plays key roles in the regulation of platelet MP formation and PS exposure. PKA-mediated MP shedding is dependent on calpain activation.
PAK Membrane Translocation and Phosphorylation Regulate Platelet Aggregation Downstream of Gi and G12/13 Pathways.

Jianjun Zhang,Yan Zhang,Shuang Zheng,Yangyang Liu,Lin Chang,Guanxing Pan,Liang Hu,Si Zhang,Junling Liu,Soochong Kim,Jianzeng Dong,Zhongren Ding

DOI: https://doi.org/10.1055/s-0040-1714745

2020-01-01

Thrombosis and Haemostasis

Abstract:Platelet activation plays a pivotal role in physiological hemostasis and pathological thrombosis causing heart attack and stroke. Previous studies conclude that simultaneous activation of Gi and G12/13 signaling pathways is sufficient to cause platelet aggregation. However, using Gq knockout mice and Gq-specific inhibitors, we here demonstrated that platelet aggregation downstream of coactivation of Gi and G12/13 depends on agonist concentrations; coactivation of Gi and G12/13 pathways only induces platelet aggregation under higher agonist concentrations. We confirmed Gi and G12/13 pathway activation by showing cAMP (cyclic adenosine monophosphate) decrease and RhoA activation in platelets stimulated at both low and high agonist concentrations. Interestingly, we found that though Akt and PAK (p21-activated kinase) translocate to the platelet membrane upon both low and high agonist stimulation, membrane-translocated Akt and PAK only phosphorylate at high agonist concentrations, correlating well with platelet aggregation downstream of concomitant Gi and G12/13 pathway activation. PAK inhibitor abolishes Akt phosphorylation, inhibits platelet aggregation in vitro and arterial thrombus formation in vivo. We propose that the PAK-PI3K/Akt pathway mediates platelet aggregation downstream of Gi and G12/13, and PAK may represent a potential antiplatelet and antithrombotic target.
A Novel Integrin-activated Pathway Forms PKB/Akt- stimulatory Phosphatidylinositol 3,4-Bisphosphate via Phosphatidylinositol 3-Phosphate in Platelets

H Banfić,X Tang,I H Batty,C P Downes,C Chen,S E Rittenhouse

DOI: https://doi.org/10.1074/jbc.273.1.13

IF: 5.485

1998-01-01

Journal of Biological Chemistry

Abstract:The aggregation of human platelets is an important physiological hemostatic event contingent upon receptor-dependent activation of the surface integrin alpha(IIb)beta(3) and subsequent binding of fabrinogen. Aggregating platelets form phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P-2), which has been reported to stimulate in vitro the activity of the proto-oncogenic protein kinase PKB/Akt, as has phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3. It has been assumed that PtdIns(3,4)P-2 is synthesized by either 5-phosphatase-catalyzed hydrolysis of PtdIns(3,4,5)P-3 produced by phosphoinositide 3-kinase (PI3K) or phosphorylation by PI3K. of PtdIns4P. We investigated the route(s) by which PtdIns(3,4)P, is formed after directly activating alpha(IIb)beta(3) with anti-ligand-induced binding site Fab fragment and report that aggregation does not lead to the generation of PtdIns(3,4,5)P-3, but to transient formation of PtdIns3P and generation of PMIns(3,4)P-2, the latter primarily by PMIns3P 4-kinase. Both this novel pathway and the activation of PKB/Akt are inhibited by the PI3K inhibitor, wort-mannin, and the calpain inhibitor, calpeptin, constituting the first evidence that PMIns(3,4)P-2 can stimulate PKB/Akt in vivo in the absence of PtdIns(3,4,5)P-3, Integrin-activated generation of the second messenger PMIns(3,4)P-2 thus depends upon a route distinct from that known to be utilized initially by growth factors. This pathway is of potential general relevance to the function of integrins.
Primary Study of Suppressive Effect and Mechanism of Resveratrol on Platelet Aggregation

YANG Yu-min,WANG Shi-jun,WANG Hong-qiang,WANG Xin-xiang,CHEN Jun-zhu

DOI: https://doi.org/10.3321/j.issn:1001-2494.2009.03.008

2009-01-01

Abstract:OBJECTIVE To observe the effects and mechanism of Resveratrol (Resv) on adenosine diphosphate (ADP)-induced platelet aggregation. METHODS Platelet aggregometer, flow cytometry and phosphorimaging system were used to study the effects of Resv and protein kinase C inhibitor (PKCI) on the ADP-induced maximal platelet aggregation rate (MPAG), platelet membrane-bound fibrinogen (PFIG), the activity of protein kinase C in membrane of platelets (M-PKC),and the rate of M-PKC in total PKC activity (T-PKC)in healthy volunteers. RESULTS Resv (25,50 and 100 μmol﹒L-1) inhibited ADP-induced MPAG and PFIG in a dose-dependent manner. PKCI and Resv had additive effect in inhibiting MPAG and PFIG. Resv (50 μmol·L-1) obviously depressed M-PKC and M-PKC/T-PKC. CONCLUSION Resv inhibits MPAG and PFIG, which mechanisms may be partly relative to the decrease of the activity of PKC of platelets.
A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Chun-Ho Shih,Tin-Bin Chiang,Wen-Jeng Wang

DOI: https://doi.org/10.1016/j.bbrc.2013.12.001

2014-01-10

Abstract:Agglucetin, a tetrameric glycoprotein (GP) Ibα agonist from Formosan Agkistrodon acutus venom, has been characterized as an agglutination inducer in human washed platelets (WPs). In platelet-rich plasma (PRP), agglucetin dramatically elicits a biphasic response of agglutination and subsequent aggregation. For clarifying the intracellular signaling events from agglutination to aggregation in human platelets, we examined the essential signaling molecules involved through the detection of protein tyrosine phosphorylation (PTP). In WPs, an anti-GPIbα monoclonal antibody (mAb) AP1, but not a Src kinase inhibitor PP1, completely inhibited agglucetin-induced agglutination. However, PP1 but not AP1 had a potent suppression on platelet aggregation by a GPVI activator convulxin. The PTP analyses showed agglucetin alone can cause a weak pattern involving sequential phosphorylation of Lyn/Fyn, Syk, SLP-76 and phospholipase Cγ2 (PLCγ2). Furthermore, a Syk-selective kinase inhibitor, piceatannol, significantly suppressed the aggregating response in agglucetin-activated PRP. Analyzed by flow cytometry, the binding capacity of fluorophore-conjugated PAC-1, a mAb recognizing activated integrin αIIbβ3, was shown to increase in agglucetin-stimulated platelets. Again, piceatannol but not PP1 had a concentration-dependent suppression on agglucetin-induced αIIbβ3 exposure. Moreover, the formation of signalosome, including Syk, SLP-76, VAV, adhesion and degranulation promoting adapter protein (ADAP) and PLCγ2, are required for platelet aggregation in agglucetin/fibrinogen-activated platelets. In addition, GPIbα-ligation via agglucetin can substantially promote the interactions between αIIbβ3 and fibrinogen. Therefore, the signal pathway of Lyn/Fyn/Syk/SLP-76/ADAP/VAV/PLCγ2/PKC is sufficient to trigger platelet aggregation in agglucetin/fibrinogen-pretreated platelets. Importantly, Syk may function as a major regulator for the response from GPIbα-initiated agglutination to integrin αIIbβ3-dependent aggregation in human platelets.
Prolonged Inhibition of Protein Kinase A Results in Metalloproteinase-Dependent Platelet Gpib Alpha Shedding

Kesheng Dai,Rong Yan,Suping Li,Yubo Fan,Fengyuan Zhuang,Changgeng Ruan

DOI: https://doi.org/10.1016/j.thromres.2008.12.044

IF: 10.407

2009-01-01

Thrombosis Research

Abstract:Introduction: The interaction of platelet glycoprotein (GP) Ib alpha with von Willebrand factor (VWF) exposed at the injured vessel wall initiates platelet adhesion and thrombus formation. Thus GPIb alpha ectodomain shedding has important implications for thrombosis and hemostasis. A disintegrin and metalloproteinase 17 (ADAM 17) was identified recently to play an essential role in agonist induced GPIb alpha shedding. Here we show that prolonged inhibition of protein kinase A (PKA) results in metalloproteinase-dependent GPIb alpha shedding.Methods and Results: GPIb alpha was shed from platelets prolongedly incubated with PKA inhibitors in a dose-dependent manner. In platelets treated with PKA inhibitor H89, the level of GPIb alpha shedding was significantly higher than that in calcium ionophore or alpha-thrombin treated platelets, however, P-selectin surface expression was significantly lower. PKA inhibition mediated GPIb alpha shedding was reversed by PKA activator forskolin and partially inhibited by membrane-permeable calpain inhibitors. Furthermore, the metalloproteinase inhibitor GM6001 or EDTA completely inhibited H89 induced GPIb alpha shedding, indicating that it was metalloproteinase-dependent. Time course experiments revealed that the maximum GPIb alpha shedding occurred at 30 minutes after treatment with PKA inhibitor. Platelets prolongedly treated with PKA inhibitor exhibited significant decrease in botrocetin-induced aggregation and shear-induced adhesion on VWF.Conclusions: These data show that prolonged inhibition of PKA results in metalloproteinase-dependent platelet GPIb alpha ectodomain shedding. This finding has physiological implications for hemostasis and limiting thrombus infinite formation after platelet activation, and it also suggests a novel strategy to develop new drugs for thrombotic diseases. (C) 2009 Elsevier Ltd. All rights reserved.
Cyclic AMP-Dependent Protein Kinase Mediates Glycoprotein Ibα Shedding from Platelet.

Kesheng Dai,Rong Yan,Hong Cheng,Richard Bodnar,Charaggeng Ruan

DOI: https://doi.org/10.1182/blood.v110.11.3653.3653

IF: 20.3

2007-01-01

Blood

Abstract:Extracellular domain of platelet glycoprotein (GP) Ibα contains ligand binding sites for von Willebrand factor (VWF) and α-thrombin. GPIbα binding to VWF exposed at the injured vessel initiates thrombus formation, thus it plays key roles in thrombosis and hemostasis. While a lot of research has been performed to elucidate the critical roles for GPIbα in platelet activation, little is known about the negative regulatory mechanisms of this adhesion receptor. Here we show that inhibition of cAMP-dependent protein kinase (PKA) resulted in the shedding of GPIbα from platelet. GPIbα was shed after platelets were incubated with PKA inhibitors (H89, PKI) in a dose-dependent manner. PKA mediated GPIbα shedding was inhibited by calpain inhibitors (MDL 28170, E64d, calpain inhibitor-I, calpain inhibitor-II) in a dose-dependent manor, suggesting that shedding of GPIbα is a result of calpain cleavage. Time course experiment revealed that PKA mediated GPIbα shedding occurred as a late event, 10 minutes after platelet activation. Flow cytometry and western-blot data suggested that the cleavage site was at N-terminal of residues 484 and 485 on GPIbα. These residues are responsible for disulfide bond linkage to GPIbβ. Though the size of GPIbα shed fragments from platelet treated with H89 was the same as platelet treated with calcium ionophore A23187 or thrombin, yet the intensity of platelet activation, the amount of GPIbα shedding, and redistribution of GPIbα were different, suggesting that the mechanism of PKA inhibition-initiated GPIbα shedding is different from the shedding caused by A23187 or thrombin. Platelets treated with the PKA inhibitor, H89, presented significant decrease in ristocetin induced platelet aggregation and platelet adhesion on VWF under shear stress. In conclusion, these data provide new evidence that inhibition of PKA results in calpain mediated GPIbα shedding which may play a role in limiting thrombus infinite formation after platelet activation.
[Effect of Arg-Gly-Asp-Ser (RGDS) Peptide on ADP-induced Signal Transduction of Activated Rat Platelet].

X H Yao,P Y Wang,Y Z Pang,J Y Su,C S Tang

DOI: https://doi.org/10.3321/j.issn:0371-0874.1998.02.010

1998-01-01

Abstract:The purpose of this work was to investigate the effect of Arg-Gly-Asp-Ser (RGDS) peptide on platelet aggregation, protein phosphorylation, protein kinase C (PKC) and mitogen-activated protein kinase (MAPK) activity during platelet activation. Experiments were performed on ADP activated rat platelets in vivo. Results showed that 50 mumol/L ADP, in addition to inducing platelet aggregation, obviously enhanced not only PKC and MAPK activities but also 95 and 66 kD protein phosphorylation. When platelets and ADP were incubated together with 50, 100, 200 mumol/L RGDS peptide it was found that the latter markedly inhibited ADP activated platelet aggregation and activation of PKC and MAPK, both in a concentration-dependently manner. RGDS peptide also inhibited 95 and 66 kD protein phosphorylation concentration-dependently and went positively with its activation of PKC and MAPK. The above result suggested that the antithrombotic effect of RGDS peptide was probably mediated through its effect on intracellular signal transduction in the ADP activation of platelets.
A Platelet Secretion Pathway Mediated By Cgmp-Dependent Protein Kinase

Zhenyu Li,Guoying Zhang,Jasna Ajdic Marjanovic,Changgeng Ruan,Xiaoping Du

DOI: https://doi.org/10.1074/jbc.M401532200

IF: 5.485

2004-01-01

Journal of Biological Chemistry

Abstract:Platelet secretion (exocytosis) is critical in amplifying platelet activation, in stabilizing thrombi, and in arteriosclerosis and vascular remodeling. The signaling mechanisms leading to secretion have not been well defined. We have shown previously that cGMP-dependent protein kinase (PKG) plays a stimulatory role in platelet activation via the glycoprotein Ib-IX pathway. Here we show that PKG also plays an important stimulatory role in mediating aggregation-dependent platelet secretion and secretion-dependent second wave platelet aggregation, particularly those induced via G(q)-coupled agonist receptors, the thromboxane A2 (TXA2) receptor, and protease-activated receptors (PARs). PKG I knock-out mouse platelets and PKG inhibitor-treated human platelets showed diminished aggregation-dependent secretion and also showed a diminished secondary wave of platelet aggregation induced by a TXA2 analog and thrombin receptor-activating peptides that were rescued by the granule content ADP. Low dose collagen-induced platelet secretion and aggregation were also reduced by PKG inhibitors. Furthermore PKG I knockout and PKG inhibitors significantly attenuated activation of the G(i) pathway that is mediated by secreted ADP. These data unveil a novel PKG-dependent platelet secretion pathway and a mechanism by which PKG promotes platelet activation.
A Stimulatory Role for Cgmp-Dependent Protein Kinase in Platelet Activation

ZY Li,XD Xi,MY Gu,R Feil,RD Ye,M Eigenthaler,F Hofmann,XP Du

DOI: https://doi.org/10.1016/s0092-8674(02)01254-0

2003-01-01

BMC News and views

Abstract:It is currently accepted that cGMP-dependent protein kinase (PKG) inhibits platelet activation. Here, we show that PKG plays an important stimulatory role in platelet activation. Expression of recombinant PKG in a reconstituted cell model enhanced von Willebrand factor (vWF)-induced activation of the platelet integrin alpha(IIb)beta(3). PKG knockout mice showed impaired platelet responses to vWF or low doses of thrombin and prolonged bleeding time. Human platelet aggregation induced by vWF or low-dose thrombin was inhibited by PKG inhibitors but enhanced by cGMP. Furthermore, a cGMP-enhancing agent, sildenafil, promoted vWF- or thrombin-induced platelet aggregation. The cGMP-stimulated platelet responses are biphasic, consisting of an initial transient stimulatory response that promotes platelet aggregation and a subsequent inhibitory response that limits the size of thrombi.
AGK Potentiates Arterial Thrombosis by Affecting Talin-1 and Αiibβ3-Mediated Bidirectional Signaling Pathway

Peng Zhang,Haojie Jiang,Mina Yang,Changlong Bi,Kandi Zhang,Dongsheng Liu,Meng Wei,Zheyi Jiang,Keyu Lv,Chao Fang,Junling Liu,Tiantian Zhang,Yanyan Xu,Junfeng Zhang

DOI: https://doi.org/10.1161/atvbaha.122.318647

2023-01-01

Arteriosclerosis Thrombosis and Vascular Biology

Abstract:Background: AGK (acylglycerol kinase) was first identified as a mitochondrial transmembrane protein that exhibits a lipid kinase function. Recent studies have established that AGK promotes cancer growth and metastasis, enhances glycolytic metabolism and function fitness of CD8 + T cells, or regulates megakaryocyte differentiation. However, the role of AGK in platelet activation and arterial thrombosis remains to be elaborated. Methods: We performed hematologic analysis using automated hematology analyzer and investigated platelets morphology by transmission electron microscope. We explored the role of AGK in platelet activation and arterial thrombosis utilizing transgenic mice, platelet functional experiments in vitro, and thrombosis models in vivo. We revealed the regulation effect of AGK on Talin-1 by coimmunoprecipitation, mass spectrometry, immunofluorescence, and Western blot. We tested the role of AGK on lipid synthesis of phosphatidic acid/lysophosphatidic acid and thrombin generation by specific Elisa kits. Results: In this study, we found that AGK depletion or AGK mutation had no effect on the platelet average volumes, the platelet microstructures, or the expression levels of the major platelet membrane receptors. However, AGK deficiency or AGK mutation conspicuously decreased multiple aspects of platelet activation, including agonists-induced platelet aggregation, granules secretion, JON/A binding, spreading on Fg (fibrinogen), and clot retraction. AGK deficiency or AGK mutation also obviously delayed arterial thrombus formation but had no effect on tail bleeding time and platelet procoagulant function. Mechanistic investigation revealed that AGK may promote Talin-1Ser425 phosphorylation and affect the αIIbβ3-mediated bidirectional signaling pathway. However, AGK does not affect lipid synthesis of phosphatidic acid/lysophosphatidic acid in platelets. Conclusions: AGK, through its kinase activity, potentiates platelet activation and arterial thrombosis by promoting Talin-1 Ser425 phosphorylation and affecting the αIIbβ3-mediated bidirectional signaling pathway.
Protein Kinase A Regulates Platelet Phosphodiesterase 3A through an A-Kinase Anchoring Protein Dependent Manner

Jawad S. Khalil,Robert Law,Zaher Raslan,Lih T. Cheah,Matthew S. Hindle,Ahmed A. Aburima,Mark T. Kearney,Khalid M. Naseem

DOI: https://doi.org/10.3390/cells13131104

IF: 6

2024-06-26

Cells

Abstract:Platelet activation is critical for haemostasis, but if unregulated can lead to pathological thrombosis. Endogenous platelet inhibitory mechanisms are mediated by prostacyclin (PGI2)-stimulated cAMP signalling, which is regulated by phosphodiesterase 3A (PDE3A). However, spatiotemporal regulation of PDE3A activity in platelets is unknown. Here, we report that platelets possess multiple PDE3A isoforms with seemingly identical molecular weights (100 kDa). One isoform contained a unique N-terminal sequence that corresponded to PDE3A1 in nucleated cells but with negligible contribution to overall PDE3A activity. The predominant cytosolic PDE3A isoform did not possess the unique N-terminal sequence and accounted for >99% of basal PDE3A activity. PGI2 treatment induced a dose and time-dependent increase in PDE3A phosphorylation which was PKA-dependent and associated with an increase in phosphodiesterase enzymatic activity. The effects of PGI2 on PDE3A were modulated by A-kinase anchoring protein (AKAP) disruptor peptides, suggesting an AKAP-mediated PDE3A signalosome. We identified AKAP7, AKAP9, AKAP12, AKAP13, and moesin expressed in platelets but focussed on AKAP7 as a potential PDE3A binding partner. Using a combination of immunoprecipitation, proximity ligation techniques, and activity assays, we identified a novel PDE3A/PKA RII/AKAP7 signalosome in platelets that integrates propagation and termination of cAMP signalling through coupling of PKA and PDE3A.

cell biology
PI3-kinase mediates activity of RhoA and interaction of RhoA with mDia1 in thrombin-induced platelet aggregation]

Guang-Xun Gao,Hong-Juan Dong,Hong-Tao Gu,Ying Gao,Yao-Zhu Pan,Yang Yang,Xie-Qun Chen

2009-01-01

Abstract:The aim of this study was to investigate the role of RhoA/mDia1 pathway in the process of thrombin-induced platelet aggregation and regulatory effect of PI3K inhibitor on this process. The human platelets were isolated from peripheral blood, the activation of RhoA, Rac1 and Cdc42 in the platelet aggregation was detected by GST pull-down assay and immune co-precipitation, the interaction of RhoA, Rac1 and Cdc42 with mDia1 and the formation of complex in the process of platelet aggregation were determined by immune coprecipitation, and the effect of PI3K inhibitor (wortmannin) on above-mentioned process was assayed. The results showed that thrombin elevated the activity of RhoA and the binding capability of RhoA with mDia1 during thrombin-induced platelet aggregation and spreading on Fg coated coverslips. Wortmannin inhibited the rising of RhoA activity and the binding level of RhoA with mDia1 induced by thrombin. Thrombin elevated the activity of Rac1 and Cdc42 during thrombin-induced platelet aggregation, but could not induce binding of Rac1 or Cdc42 with mDia1. Wortmannin could not inhibit the rising of Rac1 and Cdc42 activity induced by thrombin. It is concluded that the PI3-kinase regulates the thrombin-induced actin cytoskeleton reconstitution in platelets by RhoA-mDia1 pathway.
Amyloid β protein negatively regulates human platelet activation induced by thrombin receptor-activating protein

Daisuke Mizutani,Haruhiko Tokuda,Takashi Onuma,Kodai Uematsu,Daiki Nakashima,Kyohei Ueda,Tomoaki Doi,Yukiko Enomoto,Rie Matsushima-Nishiwaki,Shinji Ogura,Hiroki Iida,Osamu Kozawa,Toru Iwama

DOI: https://doi.org/10.1093/bbb/zbab201

2022-01-24

Abstract:Amyloid β protein deposition in cerebral vessels, a characteristic of Alzheimer's disease, is a risk factor for intracerebral hemorrhage. Amyloid β protein directly modulates human platelet function; however, the exact mechanism of action is unclear. Therefore, we investigated the effects of amyloid β protein on human platelet activation using an aggregometer with laser scattering. Amyloid β protein decreased platelet aggregation induced by thrombin receptor-activating protein, but not by collagen and ADP. Amyloid β protein also suppressed platelet aggregation induced by SCP0237 and A3227. Platelet-derived growth factor-AB secretion and phosphorylated-heat shock protein 27 release by thrombin receptor-activating protein were inhibited by amyloid β protein. Additionally, thrombin receptor-activating protein-induced phosphorylation of JNK and p38 MAP kinase was reduced by amyloid β protein. Collectively, our results strongly suggest that amyloid β protein negatively regulates protease-activated receptor-elicited human platelet activation. These findings may indicate a cause of intracerebral hemorrhage due to amyloid β protein.
Protein Kinase C–catalyzed Phosphorylation of an Inhibitory Phosphoprotein of Myosin Phosphatase is Involved in Human Platelet Secretion

Y Watanabe,M Ito,Y Kataoka,H Wada,M Koyama,JH Feng,H Shiku,M Nishikawa

DOI: https://doi.org/10.1182/blood.v97.12.3798

IF: 20.3

2001-01-01

Blood

Abstract:Protein kinase C (PKC)–potentiated inhibitory phosphoprotein of myosin phosphatase (CPI) was detected in human platelets. Like smooth muscle CPI-17, in vitro phosphorylation of platelet CPI by PKC inhibited the activity of myosin phosphatase containing the PP1δ catalytic subunit and the 130-kd myosin-binding subunit (MBS). Treatment of intact platelets with thrombin or the stable thromboxane A2 analog STA2 resulted in increased phosphorylation of both CPI and MBS at Thr-696, whereas phorbol myristate acetate (PMA) and the Ca++ ionophore ionomycin only induced CPI phosphorylation. PMA induced slow adenosine triphosphate (ATP) secretion of fura 2–loaded platelets with no change in cytosolic Ca++. The PMA-induced increase in CPI phosphorylation preceded phosphorylation of 20-kd myosin light chain (MLC20) at Ser-19 and ATP secretion. The PKC inhibitor, GF109203X, inhibited PMA-induced phosphorylation of CPI and MLC20 with similar IC50 values. These findings suggest that the activation of PKC by PMA induces MLC20phosphorylation by inhibiting myosin phosphatase through phosphorylation of CPI. STA2-induced MLC20phosphorylation was also diminished but not abolished by GF109203X, even at high concentrations that completely inhibited STA2-induced CPI phosphorylation. A combination of the Rho-kinase inhibitor Y-27632 and GF109203X led to a further decrease in STA2-induced MLC20 phosphorylation, mainly because of a significant inhibition of MBS phosphorylation at Thr-696. Inhibition of STA2-induced ATP release by Y-27632, GF109203X, or both appeared to correlate with the extent of MLC20 phosphorylation. Thus, CPI phosphorylation by PKC may participate in inhibiting myosin phosphatase, in addition to the Rho-kinase–mediated regulation of myosin phosphatase, during agonist-induced platelet secretion.
Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Wenxiu Yi,Qiang Li,Jian Shen,Lijie Ren,Xiaohui Liu,Qi Wang,Sudan He,Qingyu Wu,Hu Hu,Xinliang Mao,Li Zhu

DOI: https://doi.org/10.1371/journal.pone.0102394

IF: 3.7

2014-01-01

PLoS ONE

Abstract:The phosphatidylinositol 3-kinase (PI3K) signaling pathway is critical in modulating platelet functions. In the present study, we evaluated the effect of S14161, a recently identified pan-class I PI3K inhibitor, on platelet activation and thrombus formation. Results showed that S14161 inhibited human platelet aggregation induced by collagen, thrombin, U46619, and ADP in a dose-dependent manner. Flow cytometric studies showed that S14161 inhibited convulxin-or thrombin-induced P-selectin expression and fibrinogen binding of single platelet. S14161 also inhibited platelet spreading on fibrinogen and clot retraction, processes mediated by outside-in signaling. Using a microfluidic chamber we demonstrated that S14161 decreased platelet adhesion on collagen-coated surface by about 80%. Western blot showed that S14161 inhibited phosphorylation of Akt at both Ser473 and Thr308 sites, and GSK3 beta at Ser9 in response to collagen, thrombin, or U46619. Comparable studies showed that S14161 has a higher potential bioavailability than LY294002, a prototypical inhibitor of pan-class I PI3K. Finally, the effects of S14161 on thrombus formation in vivo were measured using a ferric chloride-induced carotid artery injury model in mice. The intraperitoneal injection of S14161 (2 mg/kg) to male C57BL/6 mice significantly extended the first occlusion time (5.05 +/- 0.99 min, n = 9) compared to the vehicle controls (3.72 +/- 0.95 min, n = 8) (P<0.05), but did not prolong the bleeding time (P>0.05). Taken together, our data showed that S14161 inhibits platelet activation and thrombus formation without significant bleeding tendency and toxicity, and considering its potential higher bioavailability, it may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.
Inhibitory Effect of Arg-Gly-Asp-Ser Peptide on Phosphorylation of Glycoprotein IIb/IIIa in Activated Rat Platelets

YAO Xinghai,WANG Peiyong,YU Wenjie,OU Hesheng,PANG Yongzheng,TANG chaoshu

DOI: https://doi.org/10.3321/j.issn:1671-167x.1998.05.009

1998-01-01

Abstract:Objective: To study the effect of Arg Gly Asp Ser(RGDS) peptide on platelet aggregation and back phosphorylation of platelet glycoprotein Ⅱb/Ⅲa during platelet activation. Methods: Immunoprecipitation extract of platelet membrane glycoprotein Ⅱb/Ⅲa, and back phosphorylation. Results: 50 μmol·L -1 ADP, while inducing platelet aggregation, obviously decreased back phosphorylation of platelet glycoprotein Ⅱb/Ⅲa. When platelet and ADP were incubated together with 100, 200 μmol·L -1 RGDS peptide it was found that RGDS peptide markedly inhibited ADP activated platelet aggregation and countered ADP induced phosphorylation of platelet glycoprotein Ⅱb/Ⅲa ( P 0.01) in a concentration dependent manner and the degree of inhibition between platelet aggregation and GP Ⅱb/Ⅲa back phosphorylation were in negative corelation ( r = -0.76 , P 0.01). Conclusion: The inhibition effect of RGDS peptide on platelet aggregation resulted from inhibiting platelet GP Ⅱb/Ⅲa phosphorylation.
Effect of Platelet Activating Factor(PAF) on the collagen induced platelet aggregation in whole blood.

Y Oura,N Sakiyama,R Ueshima,M Higuchi,E Kakishitha,K Nagai

DOI: https://doi.org/10.1055/s-0038-1643481

1987-01-01

Abstract:Studies of platelet aggregation are generally performed in p1ate1et-rich plasma(PRP) by the transmittance method. Recently, impedance aggregometry has been introduced which shows the platelet aggregability in whole blood. We compared the impedance aggregometry in whole blood with the transmittance method in PRP, with regard to collagen induced platelet aggregation. The aggregation rate in whole blood increased with increasing concentration of collagen, but remained unchanged in PRP. The factors which influence the platelet aggregation rate in whole blood were studied. CV-3988, that is the specific antagonist of PAF, acetylsalicylic acid (ASA) and phosphocreatine / creatine phosphokinase (CP/CPK) were used in order to evaluate the contribution of PAF, thromboxane and ADP in whole blood. CV-3988 dose-dependently inhibited platelet aggregation induced by collagen in whole blood, but did not inhibit the aggregation in PRP. ASA(10mM) inhibited the aggregation in whole blood incompletely too, but completely in PRP. And the inhibition of CP/CPK(CP/CPK : 1.5mM/50U/ml) was very weak in whole blood compared to that of other antagonists. The inhibitory effect of CV-3988 was investigated on the collagen induced platelet aggregation in whole blood which was pretreated with ASA ( 1 OmM ) and CP/CPK (1.5mM/50U/ml), resulting in a collagen induced aggregation in whole blood that was not completely inhibited. We conclude that there are some other different factors, which influence platelet aggregation in whole blood, in addition to thromboxane, ADP and PAF.
Advances in Research of ADP Receptors and Antagonists of Platelets

ZHUANG Xu-qin,HUO Jian-li,YANG Tian-yu,KONG Yi

DOI: https://doi.org/10.19526/j.cnki.1005-8915.2010.03.022

2010-01-01

Abstract:ADP is found to be the potent substance inducing the platelet aggregation in the early time in vivo and it plays a key role in the formation of coagulation clot and pathological arterial thrombus.The platelet aggregation induced by ADP starts by the changing of platelet morphology or the decrease of cAMP level after ADP combines with the ADP receptor.However compared with thrombin and collagen,ADP is a weak platelet agonist alone.In addition,ADP is considered as co-factor of the platelet activation for if can enhance or magnify the effects of other agonists.ADP receptor antagonists inhibit the expression,combination and the activity of the ADP receptor and thus repress the aggregation of the platelet,which is very important to the treatment of the thrombosis.Now,because of their valid antithrombotic activity and safety,the ADP receptor antagonists are widely used as clinical drugs.In this article we summarize the types of the platelet ADP receptor and several crucial receptor antagonists and provide valuable references to the research and development of these drugs.
[Role of phosphatidylinositol 3-kinase and myosin light chain kinase during the activation of thrombin receptors].

Yue Han,Hai-Li Gao,Wei Zhang,Xia Bai,Lan Dai,Wen-Hong Sheng,Ai-Ning Sun,De-Pei Wu,Zhao-Yue Wang,Chang-Geng Ruan

2009-01-01

Abstract:The objective of study was to compare the influences of wortmannin on platelet aggregation and platelet membrane surface glycoproteins GPIb expression after thrombin receptor activation, and to investigate the role of phosphatidylinositol 3-kinase (PI3-K) and myosin light chain kinase (MLCK) in the course of thrombin receptor activation. Peptide SFLLRN (PAR1-AP) and AYPGKF (PAR4-AP) were used for stimulating platelet, and the changes of platelet aggregation and GPIb were analyzed with 100 nmol/L wortmannin (inhibitor of PI3-K) and 10 micromol/L wortmannin (inhibitor of MLCK). The results indicated that the platelet activation was influenced by either concentration of wortmannin in response to PAR stimulation. Platelet aggregation was apparently inhibited by 10 micromol/L wortmannin through both PAR peptides, and was slightly inhibited by 100 nmol/L wortmannin only under PAR1-AP activation. In addition, GPIbalpha internalization was partly inhibited by 100 nmol/L wortmannin in response to PAR1 (p < 0.05 at 1, 2, 5 min) and PAR4 (p < 0.05 at 2, 5, 10 min) activation. Meanwhile, 10 micromol/L wortmannin induced little change for GPIbalpha centralisation in the course of PAR activation, with a delayed restoration of surface GPIbalpha observed under PAR1-AP activation, and no change of GPIbalpha redistribution existed under PAR4-AP activation. It is concluded that the different roles of PI3-K and MLCK exist in the course of thrombin receptor activation. PI3-K accelerates the short course of GPIb centralisation for two PAR signal pathways, while MLCK inhibits the restoration of GPIbalpha in PAR1 pathway.

[Effect of Protein Kinase A Activation on Aggregation Function of Platelets].

Role of Camp-Dependent Protein Kinase in the Regulation of Platelet Procoagulant Activity

PAK Membrane Translocation and Phosphorylation Regulate Platelet Aggregation Downstream of Gi and G12/13 Pathways.

A Novel Integrin-activated Pathway Forms PKB/Akt- stimulatory Phosphatidylinositol 3,4-Bisphosphate via Phosphatidylinositol 3-Phosphate in Platelets

Primary Study of Suppressive Effect and Mechanism of Resveratrol on Platelet Aggregation

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Prolonged Inhibition of Protein Kinase A Results in Metalloproteinase-Dependent Platelet Gpib Alpha Shedding

Cyclic AMP-Dependent Protein Kinase Mediates Glycoprotein Ibα Shedding from Platelet.

[Effect of Arg-Gly-Asp-Ser (RGDS) Peptide on ADP-induced Signal Transduction of Activated Rat Platelet].

A Platelet Secretion Pathway Mediated By Cgmp-Dependent Protein Kinase

A Stimulatory Role for Cgmp-Dependent Protein Kinase in Platelet Activation

AGK Potentiates Arterial Thrombosis by Affecting Talin-1 and Αiibβ3-Mediated Bidirectional Signaling Pathway

Protein Kinase A Regulates Platelet Phosphodiesterase 3A through an A-Kinase Anchoring Protein Dependent Manner

PI3-kinase mediates activity of RhoA and interaction of RhoA with mDia1 in thrombin-induced platelet aggregation]

Amyloid β protein negatively regulates human platelet activation induced by thrombin receptor-activating protein

Protein Kinase C–catalyzed Phosphorylation of an Inhibitory Phosphoprotein of Myosin Phosphatase is Involved in Human Platelet Secretion

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Inhibitory Effect of Arg-Gly-Asp-Ser Peptide on Phosphorylation of Glycoprotein IIb/IIIa in Activated Rat Platelets

Effect of Platelet Activating Factor(PAF) on the collagen induced platelet aggregation in whole blood.

Advances in Research of ADP Receptors and Antagonists of Platelets

[Role of phosphatidylinositol 3-kinase and myosin light chain kinase during the activation of thrombin receptors].